DK3087177T3 - Antistofproduktion ex vivo - Google Patents

Antistofproduktion ex vivo Download PDF

Info

Publication number
DK3087177T3
DK3087177T3 DK14825470.9T DK14825470T DK3087177T3 DK 3087177 T3 DK3087177 T3 DK 3087177T3 DK 14825470 T DK14825470 T DK 14825470T DK 3087177 T3 DK3087177 T3 DK 3087177T3
Authority
DK
Denmark
Prior art keywords
vivo
antibody production
antibody
production
Prior art date
Application number
DK14825470.9T
Other languages
English (en)
Inventor
Helden Paula Maria Wilhelmina Van
Mark Jeroen Kwakkenbos
Hergen Spits
Tim Beaumont
Original Assignee
Kling Biotherapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kling Biotherapeutics B V filed Critical Kling Biotherapeutics B V
Application granted granted Critical
Publication of DK3087177T3 publication Critical patent/DK3087177T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/108Orthomyxoviridae (F), e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/04Immortalised cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045RNA rev transcr viruses
    • C12N2810/6054Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
DK14825470.9T 2013-12-24 2014-12-24 Antistofproduktion ex vivo DK3087177T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Publications (1)

Publication Number Publication Date
DK3087177T3 true DK3087177T3 (da) 2022-10-03

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14825470.9T DK3087177T3 (da) 2013-12-24 2014-12-24 Antistofproduktion ex vivo

Country Status (15)

Country Link
US (3) US20170009205A1 (da)
EP (2) EP3087177B1 (da)
JP (1) JP6832705B2 (da)
CN (1) CN106029873A (da)
AU (1) AU2014370516B9 (da)
BR (1) BR112016014881B1 (da)
CA (1) CA2934660C (da)
DK (1) DK3087177T3 (da)
EA (1) EA201691112A1 (da)
ES (1) ES2927905T3 (da)
HU (1) HUE060145T2 (da)
IL (1) IL246409B (da)
MX (1) MX386674B (da)
SG (1) SG11201605126YA (da)
WO (1) WO2015099534A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2646466B1 (en) * 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
CN116554353B (zh) 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法
CN118459577B (zh) * 2024-07-09 2024-11-12 浙江康佰裕生物科技有限公司 逆转录包膜蛋白GALV env蛋白及其抗体的制备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338168B2 (en) * 2002-04-26 2012-12-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric glycoproteins and pseudotyped lentiviral vectors
WO2007019223A1 (en) * 2005-08-03 2007-02-15 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
EP1974017B2 (en) * 2005-12-09 2023-06-21 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
PL2400298T3 (pl) * 2010-05-28 2014-01-31 Hoffmann La Roche Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
EP2646466B1 (en) * 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
AU2015211480B2 (en) * 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies

Also Published As

Publication number Publication date
WO2015099534A1 (en) 2015-07-02
JP6832705B2 (ja) 2021-02-24
HUE060145T2 (hu) 2023-02-28
MX2016008345A (es) 2017-02-08
US20170009205A1 (en) 2017-01-12
EP3087177A1 (en) 2016-11-02
CA2934660C (en) 2023-03-14
AU2014370516A1 (en) 2016-07-07
BR112016014881A2 (pt) 2017-08-08
US20200149007A1 (en) 2020-05-14
BR112016014881B1 (pt) 2023-03-28
CN106029873A (zh) 2016-10-12
MX386674B (es) 2025-03-19
NZ722156A (en) 2021-08-27
US12084681B2 (en) 2024-09-10
US20240425566A1 (en) 2024-12-26
SG11201605126YA (en) 2016-07-28
IL246409A0 (en) 2016-08-31
EA201691112A1 (ru) 2017-01-30
EP4141108A1 (en) 2023-03-01
ES2927905T3 (es) 2022-11-11
BR112016014881A8 (pt) 2020-06-09
IL246409B (en) 2022-01-01
AU2014370516B9 (en) 2021-07-29
AU2014370516B2 (en) 2021-03-11
CA2934660A1 (en) 2015-07-02
JP2017500052A (ja) 2017-01-05
EP3087177B1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DOS2013000297S (es) Brazalete
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DK3065774T3 (da) Anti-CCL17-antistoffer
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3087177T3 (da) Antistofproduktion ex vivo
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
ES1078715Y (es) Mosquitera
DOS2013000134S (es) Pulsera